{"classes":[{"categories":[{"measurements":[{"comment":"Here, NA indicates median and upper limit of CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"70.93","upperLimit":"NA","value":"NA"},{"comment":"Here, NA indicates median and CI was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"289"}],"units":"Participants"}],"description":"OS was defined as the interval between the date of randomization and the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ibrutinib 420 milligram (mg) (3 \\* 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.","id":"OG000","title":"Ibrutinib+BR"},{"description":"Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo+BR"}],"paramType":"MEDIAN","populationDescription":"Intent to treat (ITT) population included all participants randomized into the study regardless of treatment actually received.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}